Progesterone Receptor: Structure, Function, and Clinical Significance

Structure and Isoforms

PR is encoded by a single gene (PGR) located on chromosome 11q22, which produces two major isoforms through alternative promoter usage: PRA (94 kDa) and PRB (114 kDa). PRB contains an additional 164 amino acids at the N-terminus (the B-upstream segment, BUS) that confers distinct transcriptional properties. Both isoforms share a common structure characteristic of nuclear receptors:

• N-terminal domain (NTD): Contains activation function 1 (AF-1), a ligand-independent activation domain responsible for basal transcriptional activity.
• DNA-binding domain (DBD): Highly conserved region with two zinc fingers that recognize and bind to progesterone response elements (PREs) in target gene promoters.
• Hinge region: Flexible linker connecting DBD and LBD.
• Ligand-binding domain (LBD): Contains activation function 2 (AF-2), which undergoes conformational change upon progesterone binding, enabling co-regulator recruitment and transcriptional activation.

The ratio of PRA to PRB varies across tissues and physiological states. PRB generally acts as a stronger transcriptional activator, while PRA can repress PRB activity, functioning as a dominant-negative regulator in certain contexts.

Signaling Pathways

PR signaling operates through both genomic and non-genomic mechanisms:

Pathological Roles and Clinical Significance

• Breast Cancer

PR is a critical biomarker in breast cancer management. Approximately 70–80% of breast cancers express estrogen receptor (ER). PR positivity correlates with better prognosis, response to endocrine therapy (tamoxifen, aromatase inhibitors), and lower risk of recurrence. However, PR expression can be downregulated by ER signaling, and PR loss is associated with endocrine resistance and more aggressive disease. The PRA/PRB ratio also influences therapeutic response; PRB-dominant tumors tend to be more responsive to progestins, while PRA-dominant tumors may exhibit resistance.

• Endometrial and Ovarian Cancers

PR expression is lost in a significant proportion of endometrial and ovarian cancers, correlating with advanced stage, high grade, and poor prognosis. PR agonists (progestins) are used therapeutically in early-stage endometrial cancer and atypical hyperplasia.

• Progesterone Resistance

Conditions such as endometriosis, uterine fibroids, and recurrent pregnancy loss are associated with progesterone resistance, characterized by reduced PR expression or altered isoform ratios. Understanding the mechanisms of progesterone resistance is essential for developing targeted therapies for these common gynecological disorders.

• Other Cancers

PR expression has been reported in meningiomas, thyroid cancers, and melanomas, though its role varies by tumor type.

Pathological Pathways in Cancer:

• Endocrine resistance: PR loss, PRA/PRB ratio imbalance, and activation of alternative growth factor pathways (EGFR, HER2, PI3K) contribute to resistance to tamoxifen and aromatase inhibitors.
• Proliferation: PR activates cyclin D1 and CDK4/6, promoting cell cycle progression.
• Apoptosis evasion: PR upregulates anti-apoptotic Bcl-2 and suppresses pro-apoptotic factors.
• Migration and invasion: PR activates Src and MAPK pathways, enhancing cell motility and metastasis.
• Stemness: PR signaling maintains cancer stem cell populations in some contexts.